Under the terms of the agreement, Cold Spring Biotech will market and sell CustomArrays and CatalogArrays, including the recently introduced influenza A research microarray.
Cold Spring has three offices in Taiwan and five offices in Mainland China. With this distributed network and appropriate contacts, Cold Spring will market CombiMatrix products in rapidly growing markets and is positioned to provide CombiMatrix’s influenza A research microarrays for testing of influenza H5N1.
“China is a fast-growing market for genetic-analysis research with growing concerns over the spread of H5N1. Our Influenza A Research Microarray is built upon a powerful platform for array-based genetic analysis, further demonstrating the versatility of the CustomArray platform across multiple applications,” said Michael Tognotti, vice president of sales and marketing for CombiMatrix.